Healthcare Tariffs: A Georgia Tech/U.C. Davis study says U.S. tariffs on imported medical supplies hit $3.4B in the first half of 2025, with about 56% passed through to providers and facilities, and could jump to $15.8B in duties under later 2025 rates. Drug Pricing Policy: Public Citizen urged lawmakers to reject Germany-style pricing rollbacks in a Section 301 review, warning weaker controls would raise prices for governments and patients. FDA Biosimilars: Teva won FDA approval for Degevma, a biosimilar to Xgeva, expanding its denosumab lineup for cancer-related bone complications. Tariff Exemptions for Pharma: New U.S. Commerce guidance outlines which specialty drug categories can be exempt from 100% tariffs and how companies can pursue reduced or zero-tariff paths tied to U.S. manufacturing. Obesity/Diabetes Pipeline: Retatrutide trial results add weight-loss and improvements in knee osteoarthritis pain and sleep apnea, while experts warn against buying bootleg retatrutide online. Microbiome Testing Investment: Tiny Health raised $33M to expand gut and vaginal microbiome testing and clinical research. Care Delivery & Evidence: Australia’s Support at Home review found major gaps in proof of agreed prices, even when delivery evidence was stronger. Hospital Consolidation: Essentia Health and HealthPartners approved a merger effective Jan. 1, 2027, aiming to expand specialists and coordinated care. AI for Clinical Ops: A healthcare AI infrastructure piece argues providers must shift focus from models to the hospital systems—networking, security, and long-term workload readiness.